NORTHVALE, N.J., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations, announced results for the fiscal second quarter ended September 30, 2011.
For the second quarter, consolidated revenues were $274,132, a decrease of 72% compared with last year's second quarter, with revenues being earned from diversified revenue streams that included the manufacturing and sale of the Phentermine and Lodrane D® products both launched this fiscal year, and lab service revenues and residual royalties related to the discontinued extended release Lodrane 24 and Lodrane 24D® products.
Operating losses increased to $591,602 from last year's second quarter operating loss of $136,807. The increase in operating losses was mainly the result of a significant decrease in revenues relating to the removal of the sustained release Lodrane products, combined with increased product development costs being incurred in connection with Elite's efforts to bring new products to the market.
The first few months of sales from the newly launched phentermine and Lodrane D® products were not sufficient to offset the loss of revenue and income from the discontinued extended release Lodrane products. Elite, however, does expect that the revenues from these newly launched products will continue to grow and we anticipate approvals soon for the three products currently under review by the FDA. In addition, we are expecting revenues to begin shortly from the first of the three contract manufacturing opportunities.
GAAP net income, including non-cash revenues and expenses relating to the accounting treatment of preferred share derivatives and the fair value of warrant derivatives, was $13,919,321, or $0.06 basic net income per share and $0.03 fully diluted net income per share.
Cash flow from operations was a negative $230,333 for the first two quarters of fiscal 2011, compared to a positive operating cash flow of $354,788 for last year's first two quarters. Net cash flow for the first two quarters, inclusive of cash used in investing and financing activities, was a negative $486,777. Cash as of September 30, 2011 was $1,339,078.
"Unfortunately this past quarter demonstrated the negative impact on revenue and profits from the loss of Lodrane extended-release manufacturing and sale while we are still in the early phases of launching our new product pipeline. We currently manufacture two products and as we have discussed before, we expect to be manufacturing additional products both for our own account and on a contract basis. It is our expectation that these additional products will enable the company to achieve positive cash flow from operations over time" stated Jerry Treppel, Elite Chairman & CEO.
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Tuesday, November 15, 2011 at 2:00 PM EST. Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until November 29, 2011 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
Financial Statements
| ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES | ||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
| ASSETS | ||||
| September 30, 2011 | March 31, 2011 | |||
| (Unaudited) | (Audited) | |||
| CURRENT ASSETS | ||||
| Cash and cash equivalents | $1,339,078 | $1,825,858 | ||
| Accounts receivable, (net of allowance for doubtful accounts of zero) | 252,659 | 571,667 | ||
| Inventories (net of allowance of $93,338 and $ 1,047,456, respectively) | 382,239 | 616,362 | ||
| Prepaid expenses and other current assets | 104,518 | 133,472 | ||
| Total current assets | 2,078,494 | 3,147,359 | ||
|
PROPERTY AND EQUIPMENT, net of accumulated depreciation and amortization of $4,427,377 and $4,189,618, respectively |
4,243,696 | 4,118,274 | ||
| INTANGIBLE ASSETS – net of accumulated amortization of zero | 613,833 | 597,556 | ||
| OTHER ASSETS | ||||
| Investment in Novel Laboratories Inc. | 3,329,322 | 3,329,322 | ||
| Security deposits | 13,725 | 28,377 | ||
| Restricted cash – debt service for EDA bonds | 287,131 | 291,420 | ||
| EDA Bond offering costs, net of accumulated amortization | ||||
| of $85,964 and $78,898, respectively | 268,488 | 275,554 | ||
| Total other assets | 3,898,666 | 3,924,673 | ||
| TOTAL ASSETS | $10,834,689 | $11,787,862 | ||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||
| September 30, 2011 | March 31, 2011 | |||
| (Unaudited) | (Audited) | |||
| CURRENT LIABILITIES | ||||
| EDA Bonds payable | $3,385,000 | $3,385,000 | ||
| Short term loans and current portion of long-term debt | 13,517 | 13,105 | ||
| Accounts payable and accrued expenses | 937,285 | 935,797 | ||
| Customer Deposits | --- | 39,400 | ||
| Deferred Revenues – Current | 13,333 | 13,333 | ||
| Preferred share derivative interest payable | 124,370 | 282,680 | ||
| Total Current Liabilities | 4,473,505 | 4,669,315 | ||
| LONG TERM LIABILITIES | ||||
| Deferred Revenues | 172,224 | 178,890 | ||
| Other long term liabilities | 75,163 | 75,463 | ||
| Derivative Liability – Preferred Shares | 16,172,177 | 14,192,329 | ||
| Derivative Liability – Warrants | 13,629,540 | 10,543,145 | ||
| Total Long-Term Liabilities | 30,049,104 | 24,989,827 | ||
| Total Liabilities | 34,522,609 | 29,659,142 | ||
| COMMITMENTS AND CONTINGENCIES: | ||||
| STOCKHOLDERS' DEFICIT | ||||
|
Common Stock – par value of $0.001, Authorized 355,516,558 Issued and outstanding – 254,779,074 shares and 180,545,657 shares, respectively |
254,780 | 180,546 | ||
| Additional paid-in capital | 108,039,275 | 97,116,044 | ||
| Accumulated deficit | (131,675,134) | (114,861,029) | ||
| Treasury stock, at cost (100,000 common shares) | (306,841) | (306,841) | ||
| Total Stockholders' Deficit | (23,687,920) | (17,871,280) | ||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $10,834,689 | $11,787,862 | ||
| ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES | ||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||
| Three Months Ended | ||
| September 30, | ||
| 2011 | 2010 | |
| (unaudited) | (unaudited) | |
| REVENUES: | ||
| Manufacturing Revenues | $78,294 | $767,341 |
| Royalties and Profit Splits | 100,069 | 169,901 |
| Lab Fee Revenues | 95,769 | 57,404 |
| Total Revenues | 274,132 | 994,646 |
| Cost of Revenues | 76,331 | 565,624 |
| Gross Profit | 197,801 | 429,022 |
| OPERATING EXPENSES | ||
| Research and Development | 198,212 | 150,436 |
| General and Administrative | 476,897 | 379,104 |
| Non-cash compensation through issuance of stock options and warrants | 6,113 | 10,329 |
| Depreciation and amortization | 108,181 | 25,960 |
| Total Operating Expenses | 789,403 | 565,829 |
| LOSS FROM OPERATIONS | (591,602) | (136,807) |
| OTHER INCOME / (EXPENSES): | ||
| Interest expense | (57,931) | (57,737) |
| Change in fair value of outstanding warrant derivatives | 10,497,037 | 900,047 |
| Change in fair value of preferred share derivatives | 4,196,187 | 1,505,333 |
| Interest expense attributable to dividends accrued to preferred share derivative liabilities | (124,370) | (306,440) |
| Discount in Series E issuance attributable to beneficial conversion features | --- | (39,132) |
| Total Other Income / (Expense) | 14,510,923 | 2,002,071 |
| INCOME BEFORE PROVISION FOR INCOME TAXES | 13,919,321 | 1,865,264 |
| Provision for Income Taxes | --- | 1,040 |
| NET INCOME | $13,919,321 | $1,864,224 |
| NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS | $13,919,321 | $1,864,224 |
| NET INCOME PER SHARE | ||
| BASIC | $0.06 | $0.02 |
| DILUTED | $0.03 | $0.01 |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDINGS | ||
| BASIC | 248,247,253 | 92,367,680 |
| DILUTED | 454,162,476 | 299,999,783 |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal ("Hi-Tech"). Elite's lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
The Elite Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8737
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. Elite undertakes no obligation to update any forward-looking statements.